N/A N=55 Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 2
Refractive Errors · Myopia
Primary: Distance Visual Acuity (VA) With Study Lenses — -0.13; -0.15 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=278 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants Achieving Mucosal Healing at Week 30 — 18.9; 14.5 percentage of participants — p==0.401
Phase 4 N=288 Extended Release Naltrexone for Opioid-Dependent Youth
Drug Dependence
Primary: Opioid Use at 6 Month Follow-up — 19.63; 18.42 days
N/A N=34 The Effect of Concord Grape Polyphenol-soy Protein Isolate Complex (GP-SPI) on Gut Microbiota
Mechanisms, Defense
Primary: Gut Microbiota Composition — 58; 30; 0.04; 7.3 percentage of bacterial phyla
N/A N=321 The MSK-Tracker Study
Musculoskeletal Pain
Primary: Patient Enablement Instrument (PEI) — 1.48; 1.50 units on a scale — p=0.96
Phase 3 N=643 Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
HIV Infections
Primary: Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery — 97.5; 91.0; 97.5; 91.4 Percentage of participants — p=0.005
Phase 2 N=19 A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
Incurable Platinum Refractory Germ Cell Tumors · Tumors
Primary: Recommended Phase 2 Dose (RP2D) of ASP1650 — 1500 Milligram per meter square (mg/m^2)
Phase 2 N=2,200 V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
Cytomegalovirus (CMV) Infections
Primary: Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)…
Phase 4 N=14 Neural Correlates In Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI) — 7.47 percent change
Phase 2 N=35 REduCing Immunogenicity to PegloticasE (RECIPE) Study
Gout Chronic
Primary: Proportion of Participants Achieving and Maintaining an sUA ≤ to 6 Milligram Per Deciliter (mg/dL) Through 12 Weeks — 19; 4; 3; 6 Participants — p=<0.01
N/A N=10 Precision Gait Retraining for Children With Cerebral Palsy
Cerebral Palsy · Gait Disorders, Neurologic
Primary: Gait Metric Accuracy — 2.01 percentage of error
Phase 4 N=184 Preoperative Antibiotics for Carpal Tunnel Release Surgery
Carpal Tunnel Syndrome
Primary: Number of Participants With Surgical Site Infection — 0; 0; 0 Participants
Phase 4 N=80 A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women
Perinatal Depression · HIV-1-infection
Primary: Number of Women Approached Who Agreed to Pre-Screening With EPDS — 240 Participants
N/A N=53 Screening Wizard, Component 1 of iCHART (Integrated Care to Help At-Risk Teens)-Feasibility/Pilot Phase
Depression · Suicidal Ideation
Primary: Personalized Referral — 22; 15; 11; 18 Recommendations — p=0.083
N/A N=28 Internet-based CBT After Stroke Pilot
Stroke · Depression
Primary: Change in Depressive Symptoms Over Time — 6 scores on scale